Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 6/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL2993097 | 0.98 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL7422031 | 0.98 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL618965 | 0.92 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Benzene SCHEMBL6273750 | 0.92 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL9766208 | 0.90 | NAPRT (0.41) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL10539991 | 0.90 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL12476946 | 0.89 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL1460187 | 0.89 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL11779483 | 0.87 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL1079036 | 0.87 | NAPRT (0.43) | ALDH1A1SMN1; SMN2TSHRNAPRTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4303646-A | BIOSYNTHESIS BY ACTINOPLANES; GLYOPEPTIDE | GRUPPO LEPETIT S.P.A. (IT) | 1981-12-01 | — | — | US | claimed |
| WO-2019182483-A1 | PEPTIDE SUBSTRATES FOR PAPAIN FAMILY CYSTEINE PEPTIDASES | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" | 2019-09-26 | — | — | WO | disclosed |
| US-20110003751-A1 | Novel Immunoregulatory Peptides, Compositions and Uses Thereof | PHARMA BIO LLC (RU) | 2011-01-06 | — | — | US | disclosed |
| US-7723567-B1 | Raffinose synthase genes and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-25 | — | — | US | disclosed |
| EP-0953643-B1 | Raffinose synthase genes and their use | SUMITOMO CHEMICAL CO (JP) | 2009-06-10 | — | — | EP | disclosed |
| WO-2009065217-A1 | NOVEL IMMUNOREGULATORY PEPTIDES, COMPOSITIONS AND USES THEREOF | IMMUNOTECH DEVELOPMENTS INC. (CA) | 2009-05-28 | — | — | WO | disclosed |
| US-7511191-B1 | Raffinose synthase genes and their use | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| CN-1161373-C | Peptides and methods of making the same | ��ķ����ŵ | 2004-08-11 | — | — | CN | disclosed |
| EP-0832900-B1 | PEPTIDE AND METHOD OF OBTAINING IT | IMMUNOTECH DEV INC (CA) | 2004-03-03 | — | — | EP | disclosed |
| US-6410515-B1 | OLIGOPEPTIDE; IMMUNOSUPPRESSANTS | IMMUNOTECH DEVELOPMENTS INC. (CA) | 2002-06-25 | — | — | US | disclosed |
| US-4123607-A | BACTERICIDES | AMERICAN CYANAMID COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4107424-A | ANTIBACTERIAL | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1978-08-15 | — | — | US | disclosed |
| US-4048431-A | BACTERICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4018972-A | Antibacterial agents cis-BM123γ1 and cis-BM123γ2 | AMERICAN CYANAMID COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4007167-A | FROM NOCARDIA | AMERICAN CYANAMID COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-4001208-A | DERIVATIVE OF AN AMINOGLYCOSIDIC ANTIBIOTIC | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYO KAI (JA) | 1977-01-04 | — | — | US | disclosed |
| US-3998795-A | (Acyl-D-α-amino acid-gly-gly-tyr-ala)1 -somatostatin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3988316-A | BY FERMENTATION OF MICROMONOSPORA | SCHERING CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
| US-3956274-A | BACTERICIDES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-05-11 | — | — | US | disclosed |
| US-3951746-A | CULTURING MICROMONOSPORA GRISEA TO PRODUCE VERDAMICIN I, SISOMICIN, ANTIBIOTIC G-418 AND GENTAMICIN A | SCHERING CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003751-A1 | Novel Immunoregulatory Peptides, Compositions and Uses Thereof | VIP, NGLY1, TSLP | ALDH1A1 4707/4885SMN1; SMN2 4532/4885TSHR 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.